Defining the Ablative Dose for Y-90 TARE

This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.

Trial Details

NCT ID

NCT07586046

Phase

PHASE2

Sponsor

Northwestern University

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres

Locations (sample)

Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

Diagnosis of hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver-dominant metastatic disease not amenable to surgical resection or ablation.
Age ≥18 years.
Child-Pugh class A or B liver function
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →